GLP-1 Family advanced
GLP-1 Agonist Immunogenicity
Immunogenicity of GLP-1 receptor agonists including anti-drug antibody formation and clinical impact.
By Encyclopeptide Editorial | 1 min read
GLP-1 immunogenicity anti-drug-antibodies ADA safety
Immunogenicity Rates
| Agent | ADA Incidence | Neutralizing ADA |
|---|---|---|
| Exenatide | 40-60% | 10-20% |
| Liraglutide | 10-20% | <5% |
| Semaglutide | 15-30% | <5% |
| Dulaglutide | 5-15% | <3% |
Factors Influencing Immunogenicity
- Sequence homology: Exenatide (53% human) vs semaglutide (94% human)
- Dosing frequency
- Route of administration
- Formulation
Chemical Identity
| Property | Value |
|---|---|
| Name | GLP-1 Agonist Immunogenicity |
| Category | GLP-1 Family |
Biological Significance
This molecule plays important roles in biological systems and has potential therapeutic applications.
References
- Encyclopeptide Database. “GLP-1 Agonist Immunogenicity” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about GLP-1 Agonist Immunogenicity with interactive quizzes on Wikipept.
Take a Quiz on Wikipept